Arrowhead to Present at Upcoming March Conferences

Home/Newsroom/

Arrowhead to Present at Upcoming...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical

company developing targeted RNAi therapeutics, today announced that the

company will make presentations at the following upcoming events.

2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual

Meeting – Los Angeles, March 4-7, 2016

March 7, 9:45 a.m. PST – Stacey Melquist, Ph.D., Arrowhead senior

scientist, and coauthors, will deliver a poster presentation titled, “Targeting

Factor 12 (F12) with a Novel RNAi Delivery Platform As a Prophylactic

Treatment for Hereditary Angioedema (HAE)”

Cowen and Company 36th Annual Healthcare Conference – Boston,

March 7-9, 2016

March 7, 4:00 p.m. EST – Chris Anzalone, Ph.D., Arrowhead

president and chief executive officer, will present a company overview

Barclays Global Healthcare Conference – Miami, March 15-17, 2016

March 17, 10:15 a.m. EST – Chris Anzalone, Ph.D., Arrowhead

president and chief executive officer, will present a company overview

Webcast links and copies of presentation materials can be accessed by

visiting the Events section of the company’s website at http://ir.arrowheadresearch.com/events.cfm.

About ARC-AAT

Arrowhead’s ARC-AAT is being investigated for the treatment of liver

disease associated with alpha-1 antitrypsin deficiency (AATD), a rare

genetic disease that severely damages the liver and lungs of affected

individuals. The mean estimated prevalence of AATD in the U.S is 1 per

3000-5000, or approximately 100,000 patients. AATD is also an important

cause of pediatric liver disease with an estimated prevalence in

children of approximately 20,000 patients, and 50-80% likely to manifest

liver disease during childhood. It is a rare disease that appears to be

frequently misdiagnosed or undiagnosed. ARC-AAT employs a novel unlocked

nucleobase analog (UNA) containing RNAi trigger molecule designed for

systemic delivery using the Dynamic Polyconjugate™ delivery

system. ARC-AAT is highly effective at knocking down the Alpha-1

antitrypsin (AAT) gene transcript and reducing the hepatic production of

the mutant AAT (Z-AAT) protein in animal models. Reduction of liver

production of the inflammatory Z-AAT protein, which is believed to be

the cause of progressive liver disease in AATD patients, is important as

it is expected to halt the progression of liver disease and potentially

allow fibrotic tissue repair. ARC-AAT was granted orphan drug

designation in both the United States and in Europe, the latter being

held on Arrowhead’s behalf by a local EU representative Pharma Gateway

AB. Arrowhead is conducting a Phase 1 clinical study of ARC-AAT, with

part A in healthy volunteers and part B in AATD patients.

About ARC-520

Arrowhead’s RNAi-based candidate ARC-520 is being investigated in the

treatment of chronic HBV infection. The small interfering RNAs (siRNAs)

in ARC-520 intervene at the mRNA level, upstream of the reverse

transcription process where current standard of care nucleotide and

nucleoside analogues act. Arrowhead is investigating ARC-520

specifically to determine if it can be used to achieve a functional

cure, which is an immune clearant state characterized by hepatitis B

s-antigen negative serum with or without seroconversion. Approximately

350-400 million people worldwide are chronically infected with the

hepatitis B virus, which can lead to cirrhosis of the liver and is

responsible for 80% of primary liver cancers globally. Arrowhead is

currently conducting Phase 2b multiple dose and combination studies in

chronic HBV patients. In clinical studies to date, the most common

reported adverse events in all subjects completing treatment were upper

respiratory infection and headache.

About ARC-F12

Arrowhead’s RNAi-based candidate ARC-F12 is in preclinical development

as a potential treatment for factor 12 (F12) mediated diseases.

Arrowhead sees clear unmet need in hereditary angioedema (HAE) and

thromboembolic diseases. The biology of factor 12 as part of the

coagulation cascade and the kinin-kallikrein system suggest that its

reduction through RNAi may present opportunities in both disease areas.

The company is currently conducting studies in order to advance ARC-F12

into clinical trials.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing

targeted RNAi therapeutics. The company is leveraging its proprietary

Dynamic Polyconjugate™ delivery platform to develop targeted

drugs based on the RNA interference mechanism that efficiently silences

disease-causing genes. Arrowhead’s pipeline includes ARC-520 and ARC-521

for chronic hepatitis B virus, ARC-AAT for liver disease associated with

alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and

thromboembolic diseases, ARC-LPA for cardiovascular disease, and

ARC-HIF2 for renal cell carcinoma.

For more information please visit http://www.arrowheadresearch.com,

or follow us on Twitter @ArrowRes.

To be added to the Company’s email list and receive news directly,

please visit

http://ir.arrowheadresearch.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including our ability to finance our operations, the

future success of our scientific studies, our ability to successfully

develop drug candidates, the timing for starting and completing clinical

trials, rapid technological change in our markets, and the enforcement

of our intellectual property rights. Arrowhead Research Corporation’s

most recent Annual Report on Form 10-K and subsequent Quarterly Reports

on Form 10-Q discuss some of the important risk factors that may affect

our business, results of operations and financial condition. We assume

no obligation to update or revise forward-looking statements to reflect

new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research

Corporation.

Source: Arrowhead Research Corporation

Arrowhead Research Corporation
Vince Anzalone, 626-304-3400
CFA
ir@arrowres.com
Investor

Relations:
The Trout Group
Chad Rubin, 646-378-2947
ir@arrowres.com
Media:
Russo

Partners
Matt Middleman, 212-845-4272
M.D.
matt.middleman@russopartnersllc.com

Source: Arrowhead Research Corporation

News Provided by Acquire Media